Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Metagenomi (MGX) Capital Expenditures (2023 - 2025)

Metagenomi (MGX) has disclosed Capital Expenditures for 3 consecutive years, with $85000.0 as the latest value for Q4 2025.

  • Quarterly Capital Expenditures fell 97.01% to $85000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $574000.0 through Dec 2025, down 81.57% year-over-year, with the annual reading at $574000.0 for FY2025, 81.57% down from the prior year.
  • Capital Expenditures for Q4 2025 was $85000.0 at Metagenomi, up from $74000.0 in the prior quarter.
  • The five-year high for Capital Expenditures was $8.9 million in Q4 2023, with the low at -$1.3 million in Q3 2024.
  • Average Capital Expenditures over 3 years is $1.1 million, with a median of $228000.0 recorded in 2023.
  • The sharpest move saw Capital Expenditures soared 591.67% in 2024, then crashed 97.01% in 2025.
  • Over 3 years, Capital Expenditures stood at $8.9 million in 2023, then plummeted by 68.19% to $2.8 million in 2024, then plummeted by 97.01% to $85000.0 in 2025.
  • According to Business Quant data, Capital Expenditures over the past three periods came in at $85000.0, $74000.0, and $127000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.